ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting several cytokine axes (T2/T22/T17/T1) and epidermal differentiation.
Originally appeared as a medical research paper:
www.pubfacts.com/detail/31356921/…l-barrier-marker
#celinadubin #celinadubinMD #atopicdermatitis #research
